◀ Back to PCNA

HDAC1 — PCNA

Protein-Protein interactions - manually collected from original source literature:

Studies that report less than 10 interactions are marked with *

• IRef Biogrid Interaction: PCNA — HDAC1 (physical association, affinity chromatography technology) Milutinovic et al., J Biol Chem 2002*
• IRef Biogrid Interaction: PCNA — HDAC1 (direct interaction, pull down) Milutinovic et al., J Biol Chem 2002*
• IRef Biogrid Interaction: PCNA — HDAC1 (physical association, affinity chromatography technology) Naryzhny et al., J Biol Chem 2004*
• IRef Hprd Interaction: PCNA — HDAC1 (in vivo) Milutinovic et al., J Biol Chem 2002*
• IRef Hprd Interaction: PCNA — HDAC1 (in vitro) Milutinovic et al., J Biol Chem 2002*
• IRef Intact Interaction: Complex of 400 proteins (association, cross-linking study) Humphries et al., Science signaling 2009
• IRef Ophid Interaction: PCNA — HDAC1 (aggregation, interologs mapping) Brown et al., Bioinformatics 2005
• IRef Ophid Interaction: PCNA — HDAC1 (aggregation, confirmational text mining) Milutinovic et al., J Biol Chem 2002*

Text-mined interactions from Literome

Hatjiharissi et al., Cancer Res 2007 (Waldenstrom Macroglobulinemia) : Other proteins up-regulated by > 1.3-fold included cyclin dependent kinases, apoptosis regulators, and histone deacetylases (HDAC)
Veliz et al., Cancer Control 2012 (Leukemia, Lymphocytic, Chronic, B-Cell...) : These investigational agents include rituximab, alemtuzumab, ofatumumab, bendamustine, high-dose methylprednisolone, lenalidomide, lumiliximab, cyclin dependent kinase inhibitors, small modular immunopharmaceuticals, Bcl-2 inhibitors, and histone deacetylase inhibitors
Brett et al., Current treatment options in oncology 2013 : Similarly, cell cycle inhibitors targeting cyclin dependent kinases as well as HDAC inhibitors have shown promise in early studies